指南与共识MDS 与骨髓增殖性肿瘤

修订版国际工作组2023年高危骨髓增生异常综合征疗效标准共识提案

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
指南 / 共识 · Blood · 2023-01-01

国际专家组36名MDS专家采用改良德尔菲法制定高危MDS疗效标准共识。IWG 2023标准修改完全缓解的血红蛋白阈值,引入有限计数恢复的完全缓解和部分血液学恢复的完全缓解作为暂定疗效标准,取消骨髓完全缓解,并标准化时间至事件终点及疗效推导与报告。

要点

  • IWG 2023标准修改完全缓解的血红蛋白阈值。
  • 引入有限计数恢复的完全缓解和部分血液学恢复的完全缓解作为暂定疗效标准。
  • 取消骨髓完全缓解,并标准化时间至事件终点及疗效报告。

核心结论

  • 更新的IWG 2023疗效标准应使以患者为中心的结局与临床试验结果在多种新机制药物涌现的时代更好地相关。

研究设计与样本

  • 国际专家组由36名MDS专家组成,采用改良德尔菲法制定共识推荐。

主要发现

  • IWG 2023标准修改完全缓解的血红蛋白阈值。
  • 引入有限计数恢复的完全缓解和部分血液学恢复的完全缓解作为暂定疗效标准。
  • 取消骨髓完全缓解。
  • 对时间至事件终点的标准化及疗效的推导与报告提出具体推荐。

关键数值与推荐

  • IWG 2023标准修改完全缓解的血红蛋白阈值。
  • 引入有限计数恢复的完全缓解和部分血液学恢复的完全缓解作为暂定疗效标准。
  • 取消骨髓完全缓解。
  • 对时间至事件终点的标准化及疗效的推导与报告提出具体推荐。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable clinical presentations and outcomes. The initial response criteria developed by the International Working Group (IWG) in 2000 have been used in clinical practice, clinical trials, regulatory reviews, and drug labels. Although the IWG criteria were revised in 2006 and 2018 (the latter focusing on lower-risk disease), limitations persist in their application to higher-risk MDS (HR-MDS) and their ability to fully capture the clinical benefits of novel investigational drugs or serve as valid surrogates for longer-term clinical end points (eg, overall survival). Further, issues related to the ambiguity and practicality of some criteria lead to variability in interpretation and interobserver inconsistency in reporting results from the same sets of data. Thus, we convened an international panel of 36 MDS experts and used an established modified Delphi process to develop consensus recommendations for updated response criteria that would be more reflective of patient-centered and clinically relevant outcomes in HR-MDS. Among others, the IWG 2023 criteria include changes in the hemoglobin threshold for complete remission (CR), the introduction of CR with limited count recovery and CR with partial hematologic recovery as provisional response criteria, the elimination of marrow CR, and specific recommendations for the standardization of time-to-event end points and the derivation and reporting of responses. The updated criteria should lead to a better correlation between patient-centered outcomes and clinical trial results in an era of multiple emerging new agents with novel mechanisms of action.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zeidan AM, Platzbecker U, Bewersdorf JP, et al. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023. PMID: 36724453. doi:10.1182/blood.2022018604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。